AUS
NZ
UK
CA
USA
IND
Healthcare
Poolbeg and HOOKIPA Provide Update on Potential Combination and Fundraise
January 07, 2025 08:52 AM GMT| By Team Kalkine MediaHighlights,Gilead Sciences Supports Proposal:,Significant HOOKIPA shareholder, Gilead Sciences, intends to vote in line with the HOOKIPA Board's recommendation and participate in the proposed $30 million+ fundraise.,Fundraise Details Amended:,HOOKIPA...
GSK Secures FDA Breakthrough Therapy Designation for Osteosarcoma Treatment
January 07, 2025 08:05 AM GMT| By Team Kalkine MediaHighlights,Breakthrough Therapy Designation:,GSK5764227 (GSK'227), a B7-H3-targeted ADC, receives FDA recognition for its potential to treat relapsed or refractory osteosarcoma, offering hope to patients with limited options.,Strong Clinical Backing:...
ConvaTec Group (LON:CTEC) Experiences 0.8% Increase in Share Price Amid Market Activity
January 07, 2025 12:00 AM GMT| By Team Kalkine MediaHighlights,ConvaTec Group (CTEC) saw a 0.8% increase in share price on Monday.,Approximately 2.56 million shares were traded, reflecting an 8% decrease in trading volume.,The company's debt-to-equity ratio stands at 85.32, signaling financial leverag...
Tristel (LON:TSTL) Stock Surpasses 50-Day Moving Average, Signaling Positive Momentum
January 07, 2025 12:00 AM GMT| By Team Kalkine MediaHighlights,Tristel (TSTL) stock surpasses its 50-day moving average.,Shares trade up by 1.0% with strong session highs.,The company declares a dividend, marking a notable increase.,Tristel plc (LON:TSTL), a company recognized for its infection preven...
GSK's Nucala (Mepolizumab) Approved for Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in China
January 03, 2025 07:42 AM GMT| By Team Kalkine MediaHighlights,GSK's Nucala (mepolizumab) has been approved by China's National Medical Products Administration for CRSwNP treatment.,The approval follows positive results from Phase III trials, demonstrating its efficacy in patients with inadequately co...
Poolbeg Pharma (LON:POLB) Shares Decline by 0.7% Amid Reduced Trading Volume
January 02, 2025 02:09 PM GMT| By Team Kalkine MediaHighlights,Price Movement,Poolbeg Pharma (LON:POLB) shares dipped 0.7%, closing at GBX 7.10.,Trading Volume,Daily trade volume fell by 76% compared to the average.,Market Metrics,The stock reflects a 50-day average of GBX 7.68 and a market cap of £35...
Roquefort Therapeutics Signs Term Sheet for Sale of Lyramid to Pleiades Pharma
January 02, 2025 07:26 AM GMT| By Team Kalkine MediaHighlights:,Sale of Lyramid,: Roquefort Therapeutics has agreed to sell its subsidiary Lyramid to Pleiades Pharma for a minimum of US$10 million, including equity in Pleiades and potentially upfront cash.,Contingencies and Exclusivity,: The deal is c...
Arecor Therapeutics Advances AT351 with Exclusive Global Licensing Agreement
December 30, 2024 11:13 AM GMT| By Team Kalkine MediaHighlights,Exclusive Licensing Secured:,Arecor licenses worldwide rights for AT351 to an undisclosed partner, supported by its Arestat platform.,Milestone-Based Payments:,Agreement includes upfront payment, development milestones, and royalties on gl...
Hemogenyx Pharmaceuticals Advances in Leukaemia Treatment with Phase I Clinical Trial of HG-CT-1
December 30, 2024 11:13 AM GMT| By Team Kalkine MediaHighlights,Initiation of Clinical Trial:,Hemogenyx Pharmaceuticals begins Phase I trial for HG-CT-1, targeting recurrent acute myeloid leukaemia (AML).,Focus on Safety and Efficacy:,Trial evaluates safety, survival rates, and clinical responses in re...
Ondine Biomedical Launches Phase III Trial for Nasal Photodisinfection Technology
December 30, 2024 11:13 AM GMT| By Team Kalkine MediaHighlights,Phase III trial initiated:,Ondine Biomedical begins large-scale clinical trial for non-antibiotic infection prevention technology, enrolling its first patient.,5,000 participants across 14 sites:,The study will assess the effectiveness of...
Hemogenyx Pharmaceuticals Opens First Clinical Site for AML CAR-T Therapy Trials
December 30, 2024 07:26 AM GMT| By Team Kalkine MediaHighlights,Hemogenyx Pharmaceuticals begins patient recruitment for Phase I trials of HG-CT-1, targeting relapsed/refractory acute myeloid leukemia (AML).,The trial aims to evaluate HG-CT-1's safety profile and its impact on survival rates, response...
Arecor Therapeutics Signs Exclusive Licensing Agreement for AT351 Ready-to-Dilute Therapy
December 30, 2024 07:23 AM GMT| By Team Kalkine MediaHighlights,Arecor partners with a global pharmaceutical-focused subsidiary for the exclusive licensing of AT351, a ready-to-dilute (RTD) liquid drug.,The agreement includes upfront, milestone payments, royalties, and a path to U.S. FDA approval withi...
RTW Biotech Celebrates CORXEL’s Strategic Advances in Cardiometabolic Innovation
December 30, 2024 07:21 AM GMT| By Team Kalkine MediaHighlights,CORXEL partners with Sanofi for exclusive rights to develop and commercialize aficamten in Greater China.,CORXEL acquires worldwide rights (excluding Greater China) for CX11, an oral GLP-1 receptor agonist targeting obesity and type 2 diab...
EKF Diagnostics Holdings plc (LON:EKF)
December 27, 2024 12:00 AM GMT| By Team Kalkine MediaHighlights,EKF Diagnostics Holdings’ (EKF) price-to-sales ratio aligns closely with the industry average.,Despite recent challenges, analysts forecast modest revenue growth in the coming years.,The company’s performance and outlook reflect stability...
Oxford Nanopore Technologies (LON:ONT) Stock Declines 10.2%, Marking a Significant Drop
December 24, 2024 02:31 PM GMT| By Team Kalkine MediaHighlights,Oxford Nanopore Technologies (ONT) stock drops by 10.2% during mid-day trading.,Trading volume increases by 54% compared to the average session.,The stock falls from a previous close of GBX 143.10 to GBX 128.50.,Shares of Oxford Nanopore T...
Insider Activity at GSK plc (LON:GSK) Highlights Share Acquisition by Jonathan Symonds
December 24, 2024 12:58 PM GMT| By Team Kalkine MediaHighlights,Jonathan Symonds, an insider at GSK plc (GSK), acquired 1,500 shares on December 20.,The transaction was executed at an average price of GBX 1,315 per share.,GSK continues to maintain a prominent position in healthcare with ongoing market...
Cambridge Cognition Holdings Plc (LON:COG) Insider Purchase Sparks Market Interest
December 24, 2024 12:51 PM GMT| By Team Kalkine MediaHighlights,Insider Nick (Philip) Rodgers acquired 31,292 shares of Cambridge Cognition Holdings Plc (COG).,The transaction occurred at GBX 32 per share, totaling £10,013.44.,Shares of LON:COG recently rose by 6.3%, reflecting renewed attention.,Insid...
AstraZeneca Withdraws EU Application for Key Lung Cancer Drug Amid Trial Setbacks
December 24, 2024 11:08 AM GMT| By Team Kalkine MediaHighlights:,Application Withdrawal:,AstraZeneca voluntarily pulls EU application for lung cancer drug datopotamab deruxtecan.,Regulatory Feedback:,Decision follows input from the European Medicines Agency’s key committee.,Revenue Targets at Risk:,Dru...
EKF Diagnostics (LON:EKF) Stock Sees Significant 10.8% Surge
December 23, 2024 10:09 AM GMT| By Team Kalkine MediaHighlights,EKF Diagnostics' stock surged 10.8% in a single trading session.,Trading volume jumped by 205% compared to its average daily volume.,The company’s robust diagnostics portfolio contributes to market optimism.,EKF Diagnostics Holdings plc (L...
Proteome Sciences Secures £1 Million Loan and Announces Leadership Changes
December 23, 2024 10:07 AM GMT| By Team Kalkine MediaHighlights:,Strategic Funding Secured:,Proteome Sciences has obtained a £1 million loan to invest in advanced mass spectrometry equipment.,Leadership Transition Announced:,Christopher Pearce will assume executive duties in 2025, with Dr. Mariola Soeh...
